Cargando…
ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
ABSTRACT: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two stage hepatectomy with inter-stage portal vein embolization (TSH/PVE) are surgical maneuvers applied in patients with advanced malignancies considered unresectable by means of convention...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315489/ https://www.ncbi.nlm.nih.gov/pubmed/32580729 http://dx.doi.org/10.1186/s12957-020-01919-3 |
_version_ | 1783550263308582912 |
---|---|
author | Bednarsch, Jan Czigany, Zoltan Sharmeen, Samara van der Kroft, Gregory Strnad, Pavel Ulmer, Tom Florian Isfort, Peter Bruners, Philipp Lurje, Georg Neumann, Ulf Peter |
author_facet | Bednarsch, Jan Czigany, Zoltan Sharmeen, Samara van der Kroft, Gregory Strnad, Pavel Ulmer, Tom Florian Isfort, Peter Bruners, Philipp Lurje, Georg Neumann, Ulf Peter |
author_sort | Bednarsch, Jan |
collection | PubMed |
description | ABSTRACT: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two stage hepatectomy with inter-stage portal vein embolization (TSH/PVE) are surgical maneuvers applied in patients with advanced malignancies considered unresectable by means of conventional liver surgery. The aim of this report is to compare the oncologic outcome and technical feasibility of ALPPS and TSH/PVE in the scenario of colorectal liver metastases (CRLM). METHODS: All consecutive patients who underwent either ALPPS or TSH/PVE for CRLM between 2011 and 2017 in one hepatobiliary center were analyzed and compared regarding perioperative and long-term oncologic outcome. RESULTS: A cohort of 58 patients who underwent ALPPS (n = 21) or TSH/PVE (n = 37) was analyzed. The median overall survival (OS) was 28 months and 34 months after ALPPS and TSH/PVE (p = 0.963), respectively. The median recurrence-free survival (RFS) was higher following ALPPS with 19 months than following TSH/PVE with 10 months, but marginally failed to achieve statistical significance (p = 0.05). There were no differences in morbidity and mortality after stages 1 and 2. Patients undergoing ALPPS due to insufficient hypertrophy after TSH/PVE (rescue-ALPPS) displayed similar oncologic outcome as patients treated by conventional ALPPS or TSH/PVE (p = 0.971). CONCLUSIONS: ALPPS and TSH/PVE show excellent technical feasibility and comparable long-term oncologic outcome in CRLM. Rescue ALPPS appears to be a viable option for patients displaying insufficient hypertrophy after a TSH/PVE approach. |
format | Online Article Text |
id | pubmed-7315489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73154892020-06-25 ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study Bednarsch, Jan Czigany, Zoltan Sharmeen, Samara van der Kroft, Gregory Strnad, Pavel Ulmer, Tom Florian Isfort, Peter Bruners, Philipp Lurje, Georg Neumann, Ulf Peter World J Surg Oncol Research ABSTRACT: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two stage hepatectomy with inter-stage portal vein embolization (TSH/PVE) are surgical maneuvers applied in patients with advanced malignancies considered unresectable by means of conventional liver surgery. The aim of this report is to compare the oncologic outcome and technical feasibility of ALPPS and TSH/PVE in the scenario of colorectal liver metastases (CRLM). METHODS: All consecutive patients who underwent either ALPPS or TSH/PVE for CRLM between 2011 and 2017 in one hepatobiliary center were analyzed and compared regarding perioperative and long-term oncologic outcome. RESULTS: A cohort of 58 patients who underwent ALPPS (n = 21) or TSH/PVE (n = 37) was analyzed. The median overall survival (OS) was 28 months and 34 months after ALPPS and TSH/PVE (p = 0.963), respectively. The median recurrence-free survival (RFS) was higher following ALPPS with 19 months than following TSH/PVE with 10 months, but marginally failed to achieve statistical significance (p = 0.05). There were no differences in morbidity and mortality after stages 1 and 2. Patients undergoing ALPPS due to insufficient hypertrophy after TSH/PVE (rescue-ALPPS) displayed similar oncologic outcome as patients treated by conventional ALPPS or TSH/PVE (p = 0.971). CONCLUSIONS: ALPPS and TSH/PVE show excellent technical feasibility and comparable long-term oncologic outcome in CRLM. Rescue ALPPS appears to be a viable option for patients displaying insufficient hypertrophy after a TSH/PVE approach. BioMed Central 2020-06-24 /pmc/articles/PMC7315489/ /pubmed/32580729 http://dx.doi.org/10.1186/s12957-020-01919-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bednarsch, Jan Czigany, Zoltan Sharmeen, Samara van der Kroft, Gregory Strnad, Pavel Ulmer, Tom Florian Isfort, Peter Bruners, Philipp Lurje, Georg Neumann, Ulf Peter ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
title | ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
title_full | ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
title_fullStr | ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
title_full_unstemmed | ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
title_short | ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
title_sort | alpps versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315489/ https://www.ncbi.nlm.nih.gov/pubmed/32580729 http://dx.doi.org/10.1186/s12957-020-01919-3 |
work_keys_str_mv | AT bednarschjan alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT cziganyzoltan alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT sharmeensamara alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT vanderkroftgregory alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT strnadpavel alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT ulmertomflorian alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT isfortpeter alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT brunersphilipp alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT lurjegeorg alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy AT neumannulfpeter alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy |